1Y Close · As of Aug 26, 2026
SK Bioscience operates in the Pharmaceuticals sector.
Legal name: SK Bioscience Co.,Ltd
In fiscal year 2025, SK Bioscience (302440) reported revenue of 651.4 billion KRW, up 143.5% from 267.5 billion KRW a year earlier.
Operating profit was -123.5 billion KRW and net income was -56.2 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 2.99 trillion KRW, with a P/B of 1.47.
These figures can be verified in the DART filing (receipt no. 20260313000936).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 651.4B | -123.5B | -56.2B |
| 2024 | 267.5B | -138.4B | -50.1B |
| 2023 | 369.5B | -12.0B | 22.3B |
Recent Filings
Payment and Dispute Resolution
Semi-Annual Report (2026.06)
Corporate Briefing (IR) (Informational Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 2 acquisition(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Payment and Dispute Resolution |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Corporate Briefing (IR) (Informational Disclosure) |
| 2026-08-10 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |
| 2026-07-29 | Corporate Briefing (IR) (Informational Disclosure) |